Abstract:

BACKGROUND: Human recombinated parathyroid hormone can significantly improve the bone formation, increase the bone mineral density and reduce the rate of bone fracture. It is receipted that parathyroid hormone plays an important role in curing postmenopausal osteoporosis.
OBJECTIVE: To investigate the efficacy of the combination therapy of human parathyroid hormone (PTH 1-34) and ibandronate in the treatment of ovariectomized rat osteoporosis.
METHODS: Thirty-two health rats were randomly divided into control group, model group, ibandronate group and ibandronate+parathyroid hormone group. Except for the control group, the rats in the other three groups received ovariectomy. At 4 weeks after surgery, normal saline, ibandronate and ibandronate+parathyroid hormone were injected subcutaneously in the latter three groups, respectively.
RESULTS AND CONCLUSION: The bone calcium content of the model rat group was significantly lower than of the other three groups, ibandronate+parathyroid hormone could improve the rat bone calcium content and bone mineral density and reduce the serum calcium and alkaline phosphatase levels, combination therapy was superior to monotherapy. In conclusion, ibandronate has a significant inhibitory effect on bone mass loss in ovariectomized osteoporosis rats. The combined use of ibandronate and parathyroid hormone can increase bone mineral content which provide the basis for the treatment of postmenopausal osteoporosis.